British HIV Association guidelines on the management of opportunistic infection in people living with HIV: considerations in pregnancy 2024.

Guideline ID: 3700 Published: 2024

British HIV Association (BHIVA)

Greig J, Bamford A, Chadwick D, et al. British HIV Association guidelines on the management of opportunistic infection in people living with HIV: considerations in pregnancy 2024. London (UK): British HIV Association (BHIVA); 2024. 29 p. [121 references]

View Original Guideline

Overview

Guideline Objective

To provide recommendations on the management of opportunistic infection in pregnant women living with human immunodeficiency virus (HIV)

Patient Population

Pregnant women living with HIV

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Guidance on pharmacologic treatment of *Pneumocystis jirovecii* pneumonia (PCP), candidiasis and cryptococcal infection, toxoplasmosis, cytomegalovirus (CMV), and *Mycobacterium avium* complex
- Neonatal considerations

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Appendix 1. Risk Associated with the Use of Drugs Used to Treat Opportunistic Infections in Pregnancy and During Breastfeeding.
- Appendix 2. Literature Searching and PICO (Population, Intervention, Comparator and Outcome) Questions.
- General Methodology.
- British HIV Association (BHIVA) Guideline Development Manual; 2021 Oct.

Implementation Tools

- Supporting People Living with HIV and Opportunistic Infections.

- BHIVA Guidelines App.

Patient Education

- Non-technical Summary; 2024.

Note: This patient information is intended to help patients better understand their health and their diagnosed disorders. Patients and their representatives should still consult with a licensed health care professional for evaluation of treatment options as well as answers to their personal medical questions.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2025 ECRI